{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:58:53Z","timestamp":1773867533850,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.anai.2019.01.004","type":"journal-article","created":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T09:11:14Z","timestamp":1547197874000},"page":"387-392.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["The efficacy of 0.1% tacrolimus ophthalmic suspension in the treatment of severe atopic keratoconjunctivitis"],"prefix":"10.1016","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7371-6558","authenticated-orcid":false,"given":"Hiroyuki","family":"Yazu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3422-8578","authenticated-orcid":false,"given":"Eisuke","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiko","family":"Aketa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat","family":"Dogru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumi","family":"Fukagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5926-5826","authenticated-orcid":false,"given":"Hiroshi","family":"Fujishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2019.01.004_bib1","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.alit.2016.12.004","article-title":"Japanese guidelines for allergic conjunctival diseases 2017","volume":"66","author":"Takamura","year":"2017","journal-title":"Allergol Int"},{"issue":"Suppl 1","key":"10.1016\/j.anai.2019.01.004_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2249.2008.03716.x","article-title":"Allergy and the eye","volume":"153","author":"Leonardi","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.anai.2019.01.004_bib3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2500\/aap.2013.34.3612","article-title":"Atopic keratoconjunctivitis","volume":"34","author":"Sy","year":"2013","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.anai.2019.01.004_bib4","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jaci.2004.10.042","article-title":"Allergic conjunctivitis: update on pathophysiology and prospects for future treatment","volume":"115","author":"Ono","year":"2005","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.01.004_bib5","first-page":"1525","article-title":"Conjunctival mast cell as a mediator of eosinophilic response in ocular allergy","volume":"14","author":"Miyazaki","year":"2008","journal-title":"Mol Vis"},{"key":"10.1016\/j.anai.2019.01.004_bib6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2332\/allergolint.11-RAI-0335","article-title":"Japanese guideline for allergic conjunctival diseases","volume":"60","author":"Takamura","year":"2011","journal-title":"Allergol Int"},{"key":"10.1016\/j.anai.2019.01.004_bib7","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s00347-017-0473-3","article-title":"[Ocular involvement in atopic dermatitis: clinical aspects and therapy]","volume":"114","author":"Maier","year":"2017","journal-title":"Ophthalmologe"},{"key":"10.1016\/j.anai.2019.01.004_bib8","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jaad.2013.10.036","article-title":"Atopic keratoconjunctivitis: a review","volume":"70","author":"Chen","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.anai.2019.01.004_bib9","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1177\/1120672118757434","article-title":"Steroid-induced ocular hypertension in the pediatric age group","volume":"28","author":"Al Hanaineh","year":"2018","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.anai.2019.01.004_bib10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1034\/j.1600-0846.2001.70203.x","article-title":"Corticosteroid-induced atrophy and barrier impairment measured by non-invasive methods in human skin","volume":"7","author":"Kolbe","year":"2001","journal-title":"Skin Res Technol"},{"key":"10.1016\/j.anai.2019.01.004_bib11","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1089\/jop.2008.0103","article-title":"A\u00a0large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis","volume":"25","author":"Ebihara","year":"2009","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.anai.2019.01.004_bib12","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1097\/ICO.0b013e31812dfab3","article-title":"Management of severe allergic conjunctivitis with topical cyclosporin a 0.05% eyedrops","volume":"26","author":"Ozcan","year":"2007","journal-title":"Cornea"},{"key":"10.1016\/j.anai.2019.01.004_bib13","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1136\/bjophthalmol-2013-304453","article-title":"Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement","volume":"98","author":"Fukushima","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.anai.2019.01.004_bib14","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ajo.2013.10.006","article-title":"Long-term follow-up of tacrolimus ointment for treatment of atopic keratoconjunctivitis","volume":"157","author":"Al-Amri","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.anai.2019.01.004_bib15","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ajo.2014.11.035","article-title":"Long-term result of maintenance treatment with tacrolimus ointment in chronic ocular graft-versus-host disease","volume":"159","author":"Jung","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.anai.2019.01.004_bib16","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.ophtha.2007.07.025","article-title":"Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases","volume":"115","author":"Miyazaki","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.anai.2019.01.004_bib17","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.ophtha.2013.03.044","article-title":"Topical cyclosporine in the treatment of allergic conjunctivitis: a meta-analysis","volume":"120","author":"Wan","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.anai.2019.01.004_bib18","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1089\/jop.2009.0087","article-title":"A\u00a0randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis","volume":"26","author":"Ohashi","year":"2010","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.anai.2019.01.004_bib19","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/ACI.0b013e32833e16e4","article-title":"Atopic keratoconjunctivitis and atopic dermatitis","volume":"10","author":"Guglielmetti","year":"2010","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.01.004_bib20","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.anai.2013.05.027","article-title":"Chemotactic responses of peripheral blood eosinophils to prostaglandin D2 in atopic keratoconjunctivitis","volume":"111","author":"Fujishima","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2019.01.004_bib21","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2165\/11310760-000000000-00000","article-title":"Useful tools for the management of atopic dermatitis","volume":"10","author":"Ricci","year":"2009","journal-title":"Am J Clin Dermatol"},{"issue":"Suppl 11","key":"10.1016\/j.anai.2019.01.004_bib22","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/ICO.0000000000000245","article-title":"Functional visual acuity assessment of severe atopic keratoconjunctivitis","volume":"33","author":"Ibrahim","year":"2014","journal-title":"Cornea"},{"key":"10.1016\/j.anai.2019.01.004_bib23","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.anai.2016.08.030","article-title":"Efficacy and safety of an eye wash solution in allergic conjunctivitis after conjunctival allergen challenge","volume":"117","author":"Yazu","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2019.01.004_bib24","first-page":"CD009078","article-title":"Topical cyclosporine for atopic keratoconjunctivitis","author":"Gonzalez-Lopez","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.anai.2019.01.004_bib25","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1468-3083.2008.02933.x","article-title":"Dramatic improvement of atopic keratoconjunctivitis after topical treatment with tacrolimus ointment restricted to the eyelids","volume":"23","author":"Zribi","year":"2009","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.anai.2019.01.004_bib26","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.ajo.2012.12.009","article-title":"Application for tacrolimus ointment in treating refractory inflammatory ocular surface diseases","volume":"155","author":"Lee","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.anai.2019.01.004_bib27","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4103\/0974-9233.164616","article-title":"Tacrolimus ointment for treatment of vernal keratoconjunctivitis","volume":"23","author":"Al-Amri","year":"2016","journal-title":"Middle East Afr J Ophthalmol"},{"key":"10.1016\/j.anai.2019.01.004_bib28","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/FPC.0b013e328364db84","article-title":"PharmGKB summary: cyclosporine and tacrolimus pathways","volume":"23","author":"Barbarino","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.anai.2019.01.004_bib29","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ophtha.2016.11.002","article-title":"Steroid-sparing effect of 0.1% tacrolimus eye drop for treatment of shield ulcer and corneal epitheliopathy in refractory allergic ocular diseases","volume":"124","author":"Miyazaki","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.anai.2019.01.004_bib30","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.immuni.2005.09.015","article-title":"IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines","volume":"23","author":"Schmitz","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.anai.2019.01.004_bib31","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/mi.2017.10","article-title":"Intelectin contributes to allergen-induced IL-25, IL-33, and TSLP expression and type 2 response in asthma and atopic dermatitis","volume":"10","author":"Yi","year":"2017","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.anai.2019.01.004_bib32","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3109\/08820538.2013.874483","article-title":"Pathogenesis of vernal keratoconjunctivitis and associated factors","volume":"30","author":"Nebbioso","year":"2015","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.anai.2019.01.004_bib33","doi-asserted-by":"crossref","first-page":"e1648","DOI":"10.1097\/MD.0000000000001648","article-title":"Dry eye in vernal keratoconjunctivitis: a cross-sectional comparative study","volume":"94","author":"Villani","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.anai.2019.01.004_bib34","doi-asserted-by":"crossref","first-page":"e727","DOI":"10.1111\/aos.13093","article-title":"High incidence of dry eye in young children with allergic conjunctivitis in Southwest China","volume":"94","author":"Chen","year":"2016","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.anai.2019.01.004_bib35","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1001\/jamaophthalmol.2018.3352","article-title":"Research questions and outcomes prioritized by patients with dry eye","volume":"136","author":"Saldanha","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.anai.2019.01.004_bib36","first-page":"020503","article-title":"Variations of dry eye disease prevalence by age, sex and geographic characteristics in China: a systematic review and meta-analysis","volume":"8","author":"Song","year":"2018","journal-title":"J\u00a0Glob Health"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120619300043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120619300043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:21:14Z","timestamp":1761052874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120619300043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S1081120619300043"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2019.01.004","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy of 0.1% tacrolimus ophthalmic suspension in the treatment of severe atopic keratoconjunctivitis","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2019.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}